Lin, Richard J. http://orcid.org/0000-0002-0834-7880
Ho, Caleb
Devlin, Sean M.
Ruiz, Josel D.
Maloy, Molly A.
Shah, Gunjan L.
Perales, Miguel-Angel
Dahi, Parastoo B.
Giralt, Sergio A.
Scordo, Michael
Schöder, Heiko
Hamlin, Paul A.
Sigler, Allison M.
Dogan, Ahmet
Sauter, Craig S.
Article History
Received: 26 February 2020
Revised: 30 April 2020
Accepted: 1 May 2020
First Online: 13 May 2020
Compliance with ethical standards
:
: CSS—consultant on advisory boards for: Juno Therapeutics, Sanofi Genzyme, Spectrum Pharmaceuticals, Novartis, Precision Biosciences, Kite, a Gilead Company and GSK. Research funds for investigator-initiated trials from: Juno Therapeutics and Sanofi Genzyme. AD—consultancy fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda, EUSA Pharma. Research grants: National Cancer Institute and Roche. CH—honoraria from Invivoscribe, Inc. PAH—research support and consulting fees from Portola Pharmaceuticals, Inc. GLS—research funding from Janssen and Amgen. MS—consultancy and research funding: Angiocrine Bioscience, Inc; consultancy: McKinsey & Company; consultancy on advisory boards for: Omeros Corporation and Kite—A Gilead Company. PBD—advisory board of Kite (Gilead). SAG—advisory board for Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz pharmaceutical, Takeda, Novartis, Kite, Spectrum Pharma; research funding from Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Takeda. MAP—honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. Research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec. The remaining authors have no conflict of interest.